On the TRAIL of a Solution to Trastuzumab Resistance in HER2+ Breast Cancer

A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.

Source: CancerNetwork - April 3, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news